Investigadores
Inicio
Investigadores
Banc de Sang i Teixits (BST) (VHIR)
Inmunoterapia Celular
Terapia con células somáticas
Innovaciones Tecnológicas y Biomodelos
Joaquim VIVES ARMENGOL
Investigador principal
Grupo de Investigación: Banc de Sang i Teixits (BST) (VHIR)
Ana Belén Alvarez Palomo
Investigador colaborador
Grupo de Investigación: Banc de Sang i Teixits (BST) (VHIR)
Angel Raya Chamorro
Investigador colaborador
Grupo de Investigación: Banc de Sang i Teixits (BST) (VHIR)
ANTONELLA CONSIGLIO GIGLIO
Investigador colaborador
Grupo de Investigación: Banc de Sang i Teixits (BST) (VHIR)
Cristina Fornaguera Puigvert
Investigador colaborador
Grupo de Investigación: Banc de Sang i Teixits (BST) (VHIR)
Cristina Prat Vidal
Investigador colaborador
Grupo de Investigación: Banc de Sang i Teixits (BST) (VHIR)
Margarita Codinach Creus
Investigador colaborador
Grupo de Investigación: Banc de Sang i Teixits (BST) (VHIR)
Martí Lecina Veciana
Investigador colaborador
Grupo de Investigación: Banc de Sang i Teixits (BST) (VHIR)
Raquel Cabrera Pérez
Investigador colaborador
Grupo de Investigación: Banc de Sang i Teixits (BST) (VHIR)
Torres A., Marin-Corral J., Adalia-Bartolome R., Briones C., Ibarz-Villamayor M., Castro P., Mañez R., Trenado J., Rodríguez L., Codinach M., Fernández-Sojo J., Coll R., Querol S., Delgadillo J., Lafuente R., Vives J.. Mesenchymal stromal cell-based therapy in the COVID-19 pandemic: results from an academic phase I/II double-blind, randomized, placebo-controlled clinical trial and reflections for the field. Cytotherapy. August 2026. DOI: 10.1016/j.jcyt.2026.102903.
Impacto: 3.2. Cuartil: Q2
Ayala-Pérez A., Fernández-Santos M.E., Vives J.. Implementation of good manufacturing practice standards in cell expansion for advanced therapy medicinal products. Medicina Clinica. April 2026. DOI: 10.1016/j.medcli.2026.107412.
Impacto: 2.1. Cuartil: Q2
Martins Braga F., Kumru H., Benito-Penalva J., Vives J., Bonet R.C., Ge W., Rodríguez L., Codinach M., de la Iglesia-López A., Gómez-Rodríguez A., Cid-Fernández J.J., Montoto-Marqués A., Vidal Samsó J.. Mesenchymal Stromal/Stem Cells in Chronic Incomplete Traumatic Spinal Cord Injury: A Phase I/II Double-Blind Placebo-Controlled Multicentre Trial. Biomedicines. April 2026. DOI: 10.3390/biomedicines14040762.
Impacto: 3.9. Cuartil: Q1
Burns J.S., Gjeta R., Lesný P., Vives J.. Plying potency assays for immunotherapy of solid tumors. Frontiers in Immunology. 24 March 2026. DOI: 10.3389/fimmu.2026.1770222.
Impacto: 5.9. Cuartil: Q1
Cabrera-Pérez R., Carreras-Sánchez I., Roig-Molina Á., López-Fernández A., Portas-Torres I., Batlle-Morera L., Vélez R., Vives J.. Preclinical Assessment in Juvenile Sheep of an Allogeneic Bone Tissue Engineering Product with Wharton’s Jelly Mesenchymal Stromal Cells. Cells. June 2025. DOI: 10.3390/cells14120862.
Impacto: 5.2. Cuartil: Q2
Güell-Alonso R., Cabrera-Pérez R., Vives J.. Immunocompatibility in transplantation: adapting to a changing therapeutic landscape. Frontiers in Immunology. 2025. DOI: 10.3389/fimmu.2025.1648534.
Impacto: 5.9. Cuartil: Q1
Chaverri D., Gallardo-Villares S., Pinto J.A., Rodríguez L., Codinach M., García-López J., Querol S., Coll R., Vives J., Granell-Escobar F.. Treatment of non-hypertrophic pseudoarthrosis of long bones with a Tissue Engineered Product loaded with autologous bone marrow-derived Mesenchymal Stromal Cells: Results from a phase IIa, prospective, randomized, parallel, pilot clinical trial comparing to iliac crest autograft. Injury. July 2024. DOI: 10.1016/j.injury.2024.111596.
Impacto: 2.2. Cuartil: Q2
Sanchez-Guijo F., Vives J., Ruggeri A., Chabannon C., Corbacioglu S., Dolstra H., Farge D., Gagelmann N., Horgan C., Kuball J., Neven B., Rintala T., Rocha V., Sanchez-Ortega I., Snowden J.A., Zwaginga J.J., Gnecchi M., Sureda A.. Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT). Cytotherapy. July 2024. DOI: 10.1016/j.jcyt.2024.02.007.
Impacto: 3.7. Cuartil: Q1
López-Fernández A., Codinach M., Coca M.I., Prat-Vidal C., Castaño J., Torrents S., Aran G., Rodríguez L., Querol S., Vives J.. Comparability exercise of critical quality attributes of clinical-grade human mesenchymal stromal cells from the Wharton's jelly: single-use stirred tank bioreactors versus planar culture systems. Cytotherapy. May 2024. DOI: 10.1016/j.jcyt.2023.08.008.
Impacto: 3.7. Cuartil: Q1
Bayes-Genis A., Gastelurrutia P., Monguió-Tortajada M., Cámara M.L., Prat-Vidal C., Cediel G., Rodríguez-Gómez L., Teis A., Revuelta-López E., Ferrer-Curriu G., Roura S., Gálvez-Montón C., Bisbal F., Vives J., Vilarrodona A., Muñoz-Guijosa C., Querol S.. Implantation of a double allogeneic human engineered tissue graft on damaged heart: insights from the PERISCOPE phase I clinical trial. eBioMedicine. April 2024. DOI: 10.1016/j.ebiom.2024.105060.
Impacto: 9.7. Cuartil: Q1
(1er decil)
López-Fernández A., Garcia-Gragera V., Lecina M., Vives J.. Identification of critical process parameters for expansion of clinical grade human Wharton's jelly-derived mesenchymal stromal cells in stirred-tank bioreactors. Biotechnology Journal. February 2024. DOI: 10.1002/biot.202300381.
Impacto: 3.2. Cuartil: Q2
Pérez-Torres Lobato M., Benitez-Carabante M.I., Alonso L., Torrents S., Castillo Flores N., Uria Oficialdegui M.L., Panesso M., Alonso-Martínez C., Oliveras M., Renedo-Miró B., Vives J., Diaz-de-Heredia C.. Mesenchymal stromal cells in the treatment of pediatric hematopoietic cell transplantation-related complications (graft vs. host disease, hemorrhagic cystitis, graft failure and poor graft function): a single center experience. Frontiers in Pediatrics. 2024. DOI: 10.3389/fped.2024.1375493.
Impacto: 2.1. Cuartil: Q2
Cabrera-Pérez R., Ràfols-Mitjans A., Roig-Molina Á., Beltramone S., Vives J., Batlle-Morera L.. Human Wharton’s jelly-derived mesenchymal stromal cells promote bone formation in immunodeficient mice when administered into a bone microenvironment. Journal of Translational Medicine. December 2023. DOI: 10.1186/s12967-023-04672-9.
Impacto: 6.1. Cuartil: Q1
Delgadillo J., Kerkelä E., Waters A., Akker E.v.d., Lechanteur C., Baudoux E., Gardiner N., De Vos J., Vives J.. A management model in blood, tissue and cell establishments to ensure rapid and sustainable patient access to advanced therapy medicinal products in Europe. Cytotherapy. December 2023. DOI: 10.1016/j.jcyt.2023.08.001.
Impacto: 3.7. Cuartil: Q1
Vives J., Sánchez-Guijo F., Gnecchi M., Zwaginga J.J.. Cell and gene therapy workforce development: the role of the International Society for Cell & Gene Therapy (ISCT) in the creation of a sustainable and skilled workforce in Europe. Cytotherapy. October 2023. DOI: 10.1016/j.jcyt.2023.06.006.
Impacto: 3.7. Cuartil: Q1
Torrents S., del Moral A.E., Codinach M., Rodríguez L., Querol S., Vives J.. Optimized reagents for immunopotency assays on mesenchymal stromal cells for clinical use. Immunologic Research. October 2023. DOI: 10.1007/s12026-023-09385-1.
Impacto: 3.3. Cuartil: Q3
Martorell L., López-Fernández A., García-Lizarribar A., Sabata R., Gálvez-Martín P., Samitier J., Vives J.. Preservation of critical quality attributes of mesenchymal stromal cells in 3D bioprinted structures by using natural hydrogel scaffolds. Biotechnology and Bioengineering. September 2023. DOI: 10.1002/bit.28381.
Impacto: 3.5. Cuartil: Q2
Torrents S., Grau-Vorster M., Vives J.. Illustrative Potency Assay Examples from Approved Therapies. Advances in Experimental Medicine and Biology. 2023. DOI: 10.1007/978-3-031-30040-0_9.
Torrents S., Grau-Vorster M., Vives J.. Potency Assays: The ‘Bugaboo’ of Stem Cell Therapy. Advances in Experimental Medicine and Biology. 2023. DOI: 10.1007/978-3-031-30040-0_3.
Fernandez-Sojo J., Delgadillo J., Vives J., Rodriguez L., Mendoza A., Azqueta C., Garcia-Buendia A., Valdivia E., Martorell L., Rubio-Lopez N., Linares M., Alonso S., Ancochea A., García-Rey E., García-Muñoz N., Medina L., Querol S.. A hub-and-spoke model to deliver effective access to chimeric antigen receptor T-cell therapy in a public health network: the Catalan Blood and Tissue Bank experience. Cytotherapy. January 2023. DOI: 10.1016/j.jcyt.2022.07.011.
Impacto: 3.7. Cuartil: Q1
Muñoz-Domínguez N., Carreras-Sánchez I., López-Fernández A., Vives J.. Optimisation of processing methods to improve success in the derivation of human multipotent mesenchymal stromal cells from cryopreserved umbilical cord tissue fragments. Cryobiology. October 2022. DOI: 10.1016/j.cryobiol.2022.08.002.
Impacto: 2.7. Cuartil: Q2
Lopez-Navas L., Torrents S., Sánchez-Pernaute R., Vives J.. Compliance in Non-Clinical Development of Cell-, Gene-, and Tissue-Based Medicines: Good Practice for Better Therapies. Stem Cells Translational Medicine. August 2022. DOI: 10.1093/stcltm/szac046.
Impacto: 6.0. Cuartil: Q1
Vives J., Hernández J., Mirabel C., Puigdomenech‐poch M., Romeo‐guitart D., Marmolejo‐martínez‐artesero S., Cabrera‐pérez R., Jaramillo J., Kumru H., García‐lópez J., Vidal‐samsó J., Navarro X., Coll‐bonet R.. Preclinical Development of a Therapy for Chronic Traumatic Spinal Cord Injury in Rats Using Human Wharton’s Jelly Mesenchymal Stromal Cells: Proof of Concept and Regulatory Compliance. Cells. July-2 2022. DOI: 10.3390/cells11142153.
Impacto: 6.0. Cuartil: Q2
Vives J., Sòria M.G., McGrath E., Magri M.. The Quality Management Ecosystem in Cell Therapy in Catalonia (Spain): An Opportunity for Integrating Standards and Streamlining Quality Compliance. Cells. July-1 2022. DOI: 10.3390/cells11132112.
Impacto: 6.0. Cuartil: Q2
Chaverri D., Vivas D., Gallardo-Villares S., Granell-Escobar F., Pinto J.A., Vives J.. A pilot study of circulating levels of TGF-β1 and TGF-β2 as biomarkers of bone healing in patients with non-hypertrophic pseudoarthrosis of long bones. Bone Reports. June 2022. DOI: 10.1016/j.bonr.2021.101157.
Muñoz-Domínguez N., Roura S., Prat-Vidal C., Vives J.. Wharton’s jelly mesenchymal stromal cells and derived extracellular vesicles as post-myocardial infarction therapeutic toolkit: An experienced view. Pharmaceutics. September 2021. DOI: 10.3390/pharmaceutics13091336.
Impacto: 6.525. Cuartil: Q1
García-Muñoz E., Vives J.. Towards the standardization of methods of tissue processing for the isolation of mesenchymal stromal cells for clinical use. Cytotechnology. June 2021. DOI: 10.1007/s10616-021-00474-3.
Impacto: 2.04. Cuartil: Q4
Garcia-Lopez J., Delgadillo J., Vilarrodona A., Querol S., Ovejo J., Coll R., Millan A., Madrigal A., Soria G., Vidal F., Vives J., Herrero M.J., Lopez I., Sauleda S., Contreras E., Grifols J.R., Guasch R., Tahull E., Puig L., Masip A., Argelagués E., Muñiz-Diaz E.. SARS-CoV-2/COVID-19 pandemic: First wave, impact, response and lessons learnt in a fully integrated Regional Blood and Tissue Bank. A narrative report. Blood Transfusion. March 2021. DOI: 10.2450/2021.0259-20.
Impacto: 5.752. Cuartil: Q2
Gastelurrutia P., Prat-Vidal C., Vives J., Coll R., Bayes-Genis A., Gálvez-Montón C.. Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience. Frontiers in Cardiovascular Medicine. 4 February 2021. DOI: 10.3389/fcvm.2021.604434.
Impacto: 5.846. Cuartil: Q2
Albu S., Kumru H., Coll R., Vives J., Vallés M., Benito-Penalva J., Rodríguez L., Codinach M., Hernández J., Navarro X., Vidal J.. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. February 2021. DOI: 10.1016/j.jcyt.2020.08.008.
Impacto: 6.196. Cuartil: Q1
Carreras-Sánchez I., López-Fernández A., Rojas-Márquez R., Vélez R., Aguirre M., Vives J.. Derivation of Mesenchymal Stromal Cells from Ovine Umbilical Cord Wharton's Jelly. Current Protocols. January 2021. DOI: 10.1002/cpz1.18.
Vives J., Rodríguez L., Coca M.I., Reales L., Cabrera-Pérez R., Martorell L.. Use of Multipotent Mesenchymal Stromal Cells, Fibrin, and Scaffolds in the Production of Clinical Grade Bone Tissue Engineering Products. Methods in Molecular Biology. 2021. DOI: 10.1007/7651_2020_280.
Ramallo M., Carreras-Sánchez I., López-Fernández A., Vélez R., Aguirre M., Feldman S., Vives J.. Advances in translational orthopaedic research with species-specific multipotent mesenchymal stromal cells derived from the umbilical cord. Histology and Histopathology. January 2021. DOI: 10.14670/HH-18-249.
Impacto: 2.13. Cuartil: Q3
García de Frutos A., González-Tartière P., Coll Bonet R., Ubierna Garcés M.T., del Arco Churruca A., Rivas García A., Matamalas Adrover A., Saló Bru G., Velazquez J.J., Vila-Canet G., García-Lopez J., Vives J., Codinach M., Rodriguez L., Bagó Granell J., Càceres Palou E.. Randomized clinical trial: expanded autologous bone marrow mesenchymal cells combined with allogeneic bone tissue, compared with autologous iliac crest graft in lumbar fusion surgery. Spine Journal. December 2020. DOI: 10.1016/j.spinee.2020.07.014.
Impacto: 4.166. Cuartil: Q1
López-Fernández A., Barro V., Ortiz-Hernández M., Manzanares M.C., Vivas D., Vives J., Vélez R., Ginebra M.P., Aguirre M.. Effect of Allogeneic Cell-Based Tissue-Engineered Treatments in a Sheep Osteonecrosis Model. Tissue Engineering - Part A. September 2020. DOI: 10.1089/ten.tea.2019.0339.
Impacto: 3.845. Cuartil: Q2
García-Fernández C., López-Fernández A., Borrós S., Lecina M., Vives J.. Strategies for large-scale expansion of clinical-grade human multipotent mesenchymal stromal cells. Biochemical Engineering Journal. 15 July 2020. DOI: 10.1016/j.bej.2020.107601.
Impacto: 3.978. Cuartil: Q2
Vivas D., Grau-Vorster M., Oliver-Vila I., García-López J., Vives J.. Evaluation of a cell-based osteogenic formulation compliant with good manufacturing practice for use in tissue engineering. Molecular Biology Reports. 1 July 2020. DOI: 10.1007/s11033-020-05588-z.
Impacto: 2.316. Cuartil: Q4
Vives J., Casademont-Roca A., Martorell L., Nogués N.. Beyond chimerism analysis: methods for tracking a new generation of cell-based medicines. Bone Marrow Transplantation. 1 July 2020. DOI: 10.1038/s41409-020-0822-8.
Impacto: 5.483. Cuartil: Q1
Samarkanova D., Rodríguez L., Vives J., Coll R., Tahull E., Azqueta C., Valdivia E., Codinach M., Farssac E., Gaitan J., Escudero J.R., Querol S.. Cord blood-derived platelet concentrates as starting material for new therapeutic blood components prepared in a public cord blood bank: From product development to clinical application. Blood Transfusion. May 2020. DOI: 10.2450/2020.0305-19.
Impacto: 3.443. Cuartil: Q2
Prat-Vidal C., Rodríguez-Gómez L., Aylagas M., Nieto-Nicolau N., Gastelurrutia P., Agustí E., Gálvez-Montón C., Jorba I., Teis A., Monguió-Tortajada M., Roura S., Vives J., Torrents-Zapata S., Coca M.I., Reales L., Cámara-Rosell M.L., Cediel G., Coll R., Farré R., Navajas D., Vilarrodona A., García-López J., Muñoz-Guijosa C., Querol S., Bayes-Genis A.. First-in-human PeriCord cardiac bioimplant: Scalability and GMP manufacturing of an allogeneic engineered tissue graft. EBioMedicine. April 2020. DOI: 10.1016/j.ebiom.2020.102729.
Impacto: 8.143. Cuartil: Q1
Vives J., Batlle-Morera L.. The challenge of developing human 3D organoids into medicines. Stem Cell Research and Therapy. 4 March 2020. DOI: 10.1186/s13287-020-1586-1.
Impacto: 6.832. Cuartil: Q1
Grau-Vorster M., López-Montañés M., Cantó E., Vives J., Oliver-Vila I., Barba P., Querol S., Rudilla F.. Characterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy. Frontiers in Immunology. 25 February 2020. DOI: 10.3389/fimmu.2020.00271.
Impacto: 7.561. Cuartil: Q1
Cabrera-Pérez R., Monguió-Tortajada M., Gámez-Valero A., Rojas-Márquez R., Borràs F.E., Roura S., Vives J.. Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: Mechanisms and implications for bioprocess development and clinical application. Stem Cell Research and Therapy. 28 November 2019. DOI: 10.1186/s13287-019-1450-3.
Impacto: 5.116. Cuartil: Q1
Grau-Vorster M., Laitinen A., Nystedt J., Vives J.. HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells: A two-site study. Stem Cell Research and Therapy. 13 June 2019. DOI: 10.1186/s13287-019-1279-9.
Impacto: 5.116. Cuartil: Q1
Roura S., Vives J.. Extracellular vesicles: Squeezing every drop of regenerative potential of umbilical cord blood. Metabolism: Clinical and Experimental. June 2019. DOI: 10.1016/j.metabol.2019.02.006.
Impacto: 6.159. Cuartil: Q1
Grau-Vorster M., Rodríguez L., Del Mazo-Barbara A., Mirabel C., Blanco M., Codinach M., Gómez S.G., Querol S., García-López J., Vives J.. Compliance with good manufacturing practice in the assessment of immunomodulation potential of clinical grade multipotent mesenchymal stromal cells derived from wharton’s jelly. Cells. May 2019. DOI: 10.3390/cells8050484.
Impacto: 4.366. Cuartil: Q2
Alvarez-Palomo B., Vives J., Casaroli-Marano R.P., Gomez S.G., Rodriguez Gómez L., Edel M.J., Giner S.Q.. Adapting cord blood collection and banking standard operating procedures for HLA-Homozygous induced pluripotent stem cells production and banking for clinical application. Journal of Clinical Medicine. April 2019. DOI: 10.3390/jcm8040476.
Impacto: 3.303. Cuartil: Q1
Vives J., Mirabel C.. Multipotent mesenchymal stromal cells from bone marrow for current and potential clinical applications. Encyclopedia of Tissue Engineering and Regenerative Medicine. 1 January 2019. DOI: 10.1016/B978-0-12-801238-3.65506-X.
GRAU-VORSTER M., RODRÍGUEZ L., TORRENTS-ZAPATA S., VIVAS D., CODINACH M., BLANCO M., OLIVER-VILA I., GARCÍA-LÓPEZ J.O.A.N., VIVES J.. Levels of IL-17F and IL-33 correlate with HLA-DR activation in clinical-grade human bone marrow–derived multipotent mesenchymal stromal cell expansion cultures. Cytotherapy. January 2019. DOI: 10.1016/j.jcyt.2018.09.009.
Impacto: 4.218. Cuartil: Q1
Vives J., Mirabel C.. Multipotent Mesenchymal Stromal Cells From Bone Marrow for Current and Potential Clinical Applications. Encyclopedia of Tissue Engineering and Regenerative Medicine: Volumes 1-3. 1 January 2019. DOI: 10.1016/B978-0-12-801238-3.65506-X.
Mirabel C., Puente-Massaguer E., Del Mazo-Barbara A., Reyes B., Morton P., Gòdia F., Vives J.. Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products. Journal of Translational Medicine. 24 October 2018. DOI: 10.1186/s12967-018-1659-4.
Impacto: 4.098. Cuartil: Q2
Vivas D., Caminal M., Oliver-Vila I., Vives J.. Derivation of Multipotent Mesenchymal Stromal Cells from Ovine Bone Marrow. Current Protocols in Stem Cell Biology. 1 February 2018. DOI: 10.1002/cpsc.43.
Oliver-Vila I., Ramírez-Moncayo C., Grau-Vorster M., Marín-Gallén S., Caminal M., Vives J.. Optimisation of a potency assay for the assessment of immunomodulative potential of clinical grade multipotent mesenchymal stromal cells. Cytotechnology. 1 February 2018. DOI: 10.1007/s10616-017-0186-0.
Impacto: 1.672. Cuartil: Q3
Prat S., Gallardo-Villares S., Vives M., Carreño A., Caminal M., Oliver-Vila I., Chaverri D., Blanco M., Codinach M., Huguet P., Ramírez J., Pinto J.A., Aguirre M., Coll R., Garcia-López J., Granell-Escobar F., Vives J.. Clinical translation of a mesenchymal stromal cell-based therapy developed in a large animal model and two case studies of the treatment of atrophic pseudoarthrosis. Journal of Tissue Engineering and Regenerative Medicine. January 2018. DOI: 10.1002/term.2323.
Impacto: 3.319. Cuartil: Q2
Chaverri D., Vives J.. Toward the clinical use of circulating biomarkers predictive of bone union. Biomarkers in Medicine. December 2017. DOI: 10.2217/bmm-2017-0180.
Impacto: 2.346. Cuartil: Q3
Caminal M., Vélez R., Rabanal R.M., Vivas D., Batlle-Morera L., Aguirre M., Barquinero J., García J., Vives J.. A reproducible method for the isolation and expansion of ovine mesenchymal stromal cells from bone marrow for use in regenerative medicine preclinical studies. Journal of Tissue Engineering and Regenerative Medicine. December 2017. DOI: 10.1002/term.2254.
Impacto: 4.089. Cuartil: Q1
Roura S., Gálvez-Montón C., Mirabel C., Vives J., Bayes-Genis A.. Mesenchymal stem cells for cardiac repair: Are the actors ready for the clinical scenario?. Stem Cell Research and Therapy. 27 October 2017. DOI: 10.1186/s13287-017-0695-y.
Impacto: 4.963. Cuartil: Q1
Reyes B., Coca M.I., Codinach M., López-Lucas M.D., del Mazo-Barbara A., Caminal M., Oliver-Vila I., Cabañas V., Lope-Piedrafita S., García-López J., Moraleda J.M., Fontecha C.G., Vives J.. Assessment of biodistribution using mesenchymal stromal cells: Algorithm for study design and challenges in detection methodologies. Cytotherapy. September 2017. DOI: 10.1016/j.jcyt.2017.06.004.
Impacto: 3.993. Cuartil: Q1
Casamayor-Genescà A., Pla A., Oliver-Vila I., Pujals-Fonts N., Marín-Gallén S., Caminal M., Pujol-Autonell I., Carrascal J., Vives-Pi M., Garcia J., Vives J.. Clinical-scale expansion of CD34<sup>+</sup> cord blood cells amplifies committed progenitors and rapid scid repopulation cells. New Biotechnology. 25 March 2017. DOI: 10.1016/j.nbt.2016.10.011.
Impacto: 3.733. Cuartil: Q1
Del Mazo-Barbara A., Nieto V., Mirabel C., Reyes B., García-López J., Oliver-Vila I., Vives J.. Streamlining the qualification of computerized systems in GxP-compliant academic cell therapy facilities. Cytotherapy. 1 September 2016. DOI: 10.1016/j.jcyt.2016.06.003.
Impacto: 3.203. Cuartil: Q2
Del Mazo-Barbara A., Mirabel C., Nieto V., Reyes B., García-López J., Oliver-Vila I., Vives J.. Qualification of computerized monitoring systems in a cell therapy facility compliant with the good manufacturing practices. Regenerative Medicine. September 2016. DOI: 10.2217/rme-2016-0066.
Impacto: 2.868. Cuartil: Q2
Codinach M., Blanco M., Ortega I., Lloret M., Reales L., Coca M.I., Torrents S., Doral M., Oliver-Vila I., Requena-Montero M., Vives J., Garcia-López J.. Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow–derived multipotent mesenchymal stromal cells. Cytotherapy. 1 September 2016. DOI: 10.1016/j.jcyt.2016.05.012.
Impacto: 3.203. Cuartil: Q2
Soler R., Orozco L., Munar A., Huguet M., López R., Vives J., Coll R., Codinach M., Garcia-Lopez J.. Final results of a phase I–II trial using ex vivo expanded autologous Mesenchymal Stromal Cells for the treatment of osteoarthritis of the knee confirming safety and suggesting cartilage regeneration. Knee. 1 August 2016. DOI: 10.1016/j.knee.2015.08.013.
Impacto: 1.976. Cuartil: Q2
Caminal M., Peris D., Fonseca C., Barrachina J., Codina D., Rabanal R.M., Moll X., Morist A., García F., Cairó J.J., Gòdia F., Pla A., Vives J.. Cartilage resurfacing potential of PLGA scaffolds loaded with autologous cells from cartilage, fat, and bone marrow in an ovine model of osteochondral focal defect. Cytotechnology. 1 August 2016. DOI: 10.1007/s10616-015-9842-4.
Impacto: 1.857. Cuartil: Q3
Oliver-Vila I., Coca M.I., Grau-Vorster M., Pujals-Fonts N., Caminal M., Casamayor-Genescà A., Ortega I., Reales L., Pla A., Blanco M., García J., Vives J.. Evaluation of a cell-banking strategy for the production of clinical grade mesenchymal stromal cells from Wharton's jelly. Cytotherapy. 1 January 2016. DOI: 10.1016/j.jcyt.2015.10.001.
Impacto: 3.203. Cuartil: Q2
Milián E., Prats E., Cairó J.J., Gòdia F., Vives J.. BHRF1 exerts an antiapoptotic effect and cell cycle arrest via Bcl-2 in murine hybridomas. Journal of Biotechnology. September 01, 2015. DOI: 10.1016/j.jbiotec.2015.06.379.
Impacto: 2.667. Cuartil: Q2
Vives J., Oliver-Vila I., Pla A.. Quality compliance in the shift from cell transplantation to cell therapy in non-pharma environments. Cytotherapy. 1 August 2015. DOI: 10.1016/j.jcyt.2015.02.002.
Impacto: 3.625. Cuartil: Q1
Vives J., Carmona G.. Guide to Cell Therapy GxP: Quality Standards in the Development of Cell-Based Medicines in Non-pharmaceutical Environments. Guide to Cell Therapy GxP: Quality Standards in the Development of Cell-Based Medicines in Non-pharmaceutical Environments. 1 January 2015. DOI: .
Caminal M., Fonseca C., Peris D., Moll X., Rabanal R.M., Barrachina J., Codina D., García F., Cairó J.J., Gòdia F., Pla A., Vives J.. Use of a chronic model of articular cartilage and meniscal injury for the assessment of long-term effects after autologous mesenchymal stromal cell treatment in sheep. New Biotechnology. 25 September 2014. DOI: 10.1016/j.nbt.2014.07.004.
Impacto: 2.898. Cuartil: Q2
Fonseca C., Caminal M., Peris D., Barrachina J., Fàbregas P.J., Garcia F., Cairó J.J., Gòdia F., Pla A., Vives J.. An arthroscopic approach for the treatment of osteochondral focal defects with cell-free and cell-loaded PLGA scaffolds in sheep. Cytotechnology. March 2014. DOI: 10.1007/s10616-013-9581-3.
Impacto: 1.752. Cuartil: Q3
Caminal M., Moll X., Codina D., Rabanal R.M., Morist A., Barrachina J., Garcia F., Pla A., Vives J.. Transitory improvement of articular cartilage characteristics after implantation of polylactide:Polyglycolic acid (PLGA) scaffolds seeded with autologous mesenchymal stromal cells in a sheep model of critical-sized chondral defect. Biotechnology Letters. October 2014. DOI: 10.1007/s10529-014-1585-3.
Impacto: 1.591. Cuartil: Q3
Vélez R., Hernández-Fernández A., Caminal M., Vives J., Soldado F., Fernández A., Pla A., Aguirre M.. Treatment of femoral head osteonecrosis with advanced cell therapy in sheep. Archives of Orthopaedic and Trauma Surgery. November 2012. DOI: 10.1007/s00402-012-1584-6.
Impacto: 1.358. Cuartil: Q3
Hook L., Vives J., Fulton N., Leveridge M., Lingard S., Bootman M.D., Falk A., Pollard S.M., Allsopp T.E., Dalma-Weiszhausz D., Tsukamoto A., Uchida N., Gorba T.. Non-immortalized human neural stem (NS) cells as a scalable platform for cellular assays. Neurochemistry International. September 2011. DOI: 10.1016/j.neuint.2011.06.024.
Impacto: 2.857. Cuartil: Q2
Uhde C.W., Vives J., Jaeger I., Li M.. Rmst is a novel marker for the mouse ventral mesencephalic floor plate and the anterior dorsal midline cells. PLoS ONE. 8 January 2010. DOI: 10.1371/journal.pone.0008641.
Impacto: 4.411. Cuartil: Q1
(1er decil)
Juanola S., Vives J., Milián E., Prats E., Cairó J.J., Gòdia F.. Expression of BHRF1 improves survival of murine hybridoma cultures in batch and continuous modes. Applied Microbiology and Biotechnology. May 2009. DOI: 10.1007/s00253-008-1820-8.
Impacto: 2.896. Cuartil: Q2
Vives J., Sasajala P., Kuo H.C., Zhao S., Li M.. A mouse model for tracking nigrostriatal dopamine neuron axon growth. Genesis. March 2008. DOI: 10.1002/dvg.20375.
Impacto: 2.217. Cuartil: Q3
Zhao S., Maxwell S., Jimenez-Beristain A., Vives J., Kuehner E., Zhao J., O'Brien C., De Felipe C., Semina E., Li M.. Generation of embryonic stem cells and transgenic mice expressing green fluorescence protein in midbrain dopaminergic neurons. European Journal of Neuroscience. March 2004. DOI: 10.1111/j.1460-9568.2004.03206.x.
Impacto: 3.82. Cuartil: N/D
Vives J., Juanola S., Cairó J.J., Gòdia F.. Metabolic engineering of apoptosis in cultured animal cells: Implications for the biotechnology industry. Metabolic Engineering. April 2003. DOI: 10.1016/S1096-7176(03)00024-7.
Impacto: 3.397. Cuartil: N/D
Vives J., Juanola S., Cairó J.J., Prats E., Cornudella L., Gòdia F.. Protective effect of viral homologues of bcl-2 on hybridoma cells under apoptosis-inducing conditions. Biotechnology Progress. January-February 2003. DOI: 10.1021/bp0255715.
Impacto: 1.488. Cuartil: N/D
Tintó A., Gabernet C., Vives J., Prats E., Cairó J.J., Cornudella L., Gòdia F.. The protection of hybridoma cells from apoptosis by caspase inhibition allows culture recovery when exposed to non-inducing conditions. Journal of Biotechnology. 23 May 2002. DOI: 10.1016/S0168-1656(02)00012-3.
Impacto: 2.202. Cuartil: N/D